Eligard(R) six-month formulation successfully completes European approval...( VANCOUVER Aug. 31 / QLT USA Inc. ...),Health

VANCOUVER, Aug. 31 /PRNewswire-FirstCall/ - QLT USA, Inc., a subsidiary of QLT Inc. (NASDAQ: QLTI; TSX: QLT), announced today that the European approval procedure for the Eligard(R) 45 mg six-month formulation was successfully completed. Launch of this formulation in 23 European countries is expected to follow the implementation of this positive decision in each of the individual countries. The 6-month formulation was launched in Germany in March 2007 following its approval in December 2006. Eligard is already approved in Germany and other European countries for the one-month (7.5 mg) and three-month (22.5 mg) formulations.

"The six-month formulation provides physicians with a new convenient option for patients with prostate cancer," said Bob Butchofsky, President and Chief Executive Officer of QLT Inc. "Eligard sales have been strong recently and we believe that this new approval will help contribute to future product growth."

Through the first six months of 2007, Eligard worldwide sales have been approximately US$86.4 million. Based on the strong trend in Eligard sales during the first half of the year in July the Company raised its annual guidance on Eligard sales to project a range of US$160 million to US$180 million, an increase over previously announced guidance of US$140 million to US$160 million.

About Eligard

Eligard, a palliative treatment for advanced prostate cancer, incorporates a luteinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with QLT USA's proprietary Atrigel(R) Delivery System. The Atrigel technology allows for sustained delivery of leuprolide acetate for periods ranging from one to six months.

Eligard works by lowering the leve
'/>"/>